Medical treatment of normal tension glaucoma
- PMID: 12204707
- DOI: 10.1016/s0039-6257(02)00322-3
Medical treatment of normal tension glaucoma
Abstract
Normal-tension glaucoma was previously thought to be pressure insensitive, as medical treatment hardly reduced intraocular pressure and it did not prevent visual field loss. In the last decade, however, evidence has shown that the treatment of normal-tension glaucoma by lowering intraocular pressure can slow the deterioration of visual fields, hence the glaucomatous process. It was shown that a reduction of IOP of at least 30% is needed to induce a favorable alteration in the course of normal-tension glaucoma. New agents, such as prostaglandin analogs, the alpha(2)-adrenoceptor agonist brimonidine, and carbonic anhydrase inhibitors, have become available and may be of use in the treatment of normal-tension glaucoma. Monotherapy with prostaglandin analogs may meet the target of a reduction of IOP with 30%, but combination therapy will be needed in many cases. Few studies have been performed with brimonidine, travoprost, and bimatoprost, and it is suggested that more attention should be given to studies with these agents, as about 30% of patients with open angles and glaucomatous visual field defects have normal-tension glaucoma. Although neuroprotection is the goal of the future, no hard data are available yet which demonstrate that treatment with these agents will indeed result in preservation of visual fields.
Similar articles
-
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.Clin Ther. 2006 Apr;28(4):552-9. doi: 10.1016/j.clinthera.2006.04.007. Clin Ther. 2006. PMID: 16750466 Clinical Trial.
-
Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.Clin Exp Ophthalmol. 2006 Nov;34(8):755-64. doi: 10.1111/j.1442-9071.2006.01237.x. Clin Exp Ophthalmol. 2006. PMID: 17073898
-
Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.Surv Ophthalmol. 2004 Mar;49 Suppl 1:S12-8. doi: 10.1016/j.survophthal.2003.12.015. Surv Ophthalmol. 2004. PMID: 15016557 Clinical Trial.
-
Prostaglandin analog treatment of glaucoma and ocular hypertension.Ann Pharmacother. 2002 Mar;36(3):504-11. doi: 10.1345/aph.1A178. Ann Pharmacother. 2002. PMID: 11895065 Review.
-
Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S105-15. doi: 10.1016/s0039-6257(02)00327-2. Surv Ophthalmol. 2002. PMID: 12204706 Review.
Cited by
-
Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types.Am J Pathol. 2006 Dec;169(6):1976-89. doi: 10.2353/ajpath.2006.060400. Am J Pathol. 2006. PMID: 17148662 Free PMC article.
-
Safe trabeculectomy technique: long term outcome.Br J Ophthalmol. 2006 Jan;90(1):44-7. doi: 10.1136/bjo.2005.072884. Br J Ophthalmol. 2006. PMID: 16361666 Free PMC article.
-
Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.Biomark Insights. 2008 Jul 8;3:387-402. doi: 10.4137/bmi.s692. Biomark Insights. 2008. PMID: 19578520 Free PMC article.
-
Neuroprotection for treatment of glaucoma in adults.Cochrane Database Syst Rev. 2017 Jan 25;1(1):CD006539. doi: 10.1002/14651858.CD006539.pub4. Cochrane Database Syst Rev. 2017. PMID: 28122126 Free PMC article. Review.
-
Neuroprotection for treatment of glaucoma in adults.Cochrane Database Syst Rev. 2013 Feb 28;2(2):CD006539. doi: 10.1002/14651858.CD006539.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2017 Jan 25;1:CD006539. doi: 10.1002/14651858.CD006539.pub4. PMID: 23450569 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
